217 related articles for article (PubMed ID: 29497000)
1. A potent complement factor C3-specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement.
Jensen RK; Pihl R; Gadeberg TAF; Jensen JK; Andersen KR; Thiel S; Laursen NS; Andersen GR
J Biol Chem; 2018 Apr; 293(17):6269-6281. PubMed ID: 29497000
[TBL] [Abstract][Full Text] [Related]
2. A Complement C3-Specific Nanobody for Modulation of the Alternative Cascade Identifies the C-Terminal Domain of C3b as Functional in C5 Convertase Activity.
Pedersen H; Jensen RK; Jensen JMB; Fox R; Pedersen DV; Olesen HG; Hansen AG; Christiansen D; Mazarakis SMM; Lojek N; Hansen P; Gadeberg TAF; Zarantonello A; Laursen NS; Mollnes TE; Johnson MB; Stevens B; Thiel S; Andersen GR
J Immunol; 2020 Oct; 205(8):2287-2300. PubMed ID: 32938727
[TBL] [Abstract][Full Text] [Related]
3. A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system.
Pedersen H; Jensen RK; Hansen AG; Gadeberg TAF; Thiel S; Laursen NS; Andersen GR
J Biol Chem; 2020 Jun; 295(26):8746-8758. PubMed ID: 32376685
[TBL] [Abstract][Full Text] [Related]
4. Structure-Guided Engineering of a Complement Component C3-Binding Nanobody Improves Specificity and Adds Cofactor Activity.
Pedersen H; Jensen RK; Hansen AG; Petersen SV; Thiel S; Laursen NS; Andersen GR
Front Immunol; 2022; 13():872536. PubMed ID: 35935935
[TBL] [Abstract][Full Text] [Related]
5. An Ultrahigh-Affinity Complement C4b-Specific Nanobody Inhibits In Vivo Assembly of the Classical Pathway Proconvertase.
Zarantonello A; Presumey J; Simoni L; Yalcin E; Fox R; Hansen A; Olesen HG; Thiel S; Johnson MB; Stevens B; Laursen NS; Carroll MC; Andersen GR
J Immunol; 2020 Sep; 205(6):1678-1694. PubMed ID: 32769120
[TBL] [Abstract][Full Text] [Related]
6. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor.
Rooijakkers SH; Wu J; Ruyken M; van Domselaar R; Planken KL; Tzekou A; Ricklin D; Lambris JD; Janssen BJ; van Strijp JA; Gros P
Nat Immunol; 2009 Jul; 10(7):721-7. PubMed ID: 19503103
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1.
Nilsson-Ekdahl K; Nilsson B
Eur J Immunol; 2001 Apr; 31(4):1047-54. PubMed ID: 11298329
[TBL] [Abstract][Full Text] [Related]
8. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement.
Katschke KJ; Stawicki S; Yin J; Steffek M; Xi H; Sturgeon L; Hass PE; Loyet KM; Deforge L; Wu Y; van Lookeren Campagne M; Wiesmann C
J Biol Chem; 2009 Apr; 284(16):10473-9. PubMed ID: 19196712
[TBL] [Abstract][Full Text] [Related]
10. Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications.
Subías Hidalgo M; Yébenes H; Rodríguez-Gallego C; Martín-Ambrosio A; Domínguez M; Tortajada A; Rodríguez de Córdoba S; Llorca O
Eur J Immunol; 2017 Mar; 47(3):504-515. PubMed ID: 28083930
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the Complement Alternative Pathway by Chemically Modified DNA Aptamers That Bind with Picomolar Affinity to Factor B.
Xu X; Zhang C; Denton DT; O'Connell D; Drolet DW; Geisbrecht BV
J Immunol; 2021 Feb; 206(4):861-873. PubMed ID: 33419768
[TBL] [Abstract][Full Text] [Related]
12. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement.
Pangburn MK; Müller-Eberhard HJ
J Exp Med; 1980 Oct; 152(4):1102-14. PubMed ID: 6903192
[TBL] [Abstract][Full Text] [Related]
13. Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity.
Wen Y; Ouyang Z; Schoonooghe S; Luo S; De Baetselier P; Lu W; Muyldermans S; Raes G; Zheng F
Immunobiology; 2017 Jun; 222(6):807-813. PubMed ID: 27889311
[TBL] [Abstract][Full Text] [Related]
14. An affinity for complement C3 as a possible reason for the potency of naturally occurring antibodies in mediating tissue homeostasis.
Lutz HU; Fasler S; Stammler P
Beitr Infusionsther; 1989; 24():193-9. PubMed ID: 2481539
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
Kievits F; Kijlstra A
Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
[TBL] [Abstract][Full Text] [Related]
16. The covalent interaction of C3 with IgG immune complexes.
Vivanco F; Muñoz E; Vidarte L; Pastor C
Mol Immunol; 1999; 36(13-14):843-52. PubMed ID: 10698338
[TBL] [Abstract][Full Text] [Related]
17. Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein.
Hebecker M; Józsi M
J Biol Chem; 2012 Jun; 287(23):19528-36. PubMed ID: 22518841
[TBL] [Abstract][Full Text] [Related]
18. Filtration and tubular handling of EWE-hC3Nb1, a complement inhibitor nanobody, in wild type mice and a mouse model of proteinuric kidney disease.
Fast MS; Weyer K; Pedersen H; Andersen GR; Birn H
FEBS Open Bio; 2024 Feb; 14(2):322-330. PubMed ID: 38124617
[TBL] [Abstract][Full Text] [Related]
19. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.
Subías M; Tortajada A; Gastoldi S; Galbusera M; López-Perrote A; Lopez Lde J; González-Fernández FA; Villegas-Martínez A; Dominguez M; Llorca O; Noris M; Morgan BP; Rodríguez de Córdoba S
J Immunol; 2014 Dec; 193(11):5567-75. PubMed ID: 25355917
[TBL] [Abstract][Full Text] [Related]
20. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
Mayes JT; Schreiber RD; Cooper NR
J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
